Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1

Current share price for AT1 : $0.017 -0.021 (-55.26%)⁺

Announcement

Appendix 4D and Half Year Report ended 31 Dec 2025

Release

26 Feb 2026 9:41AM

Price at Release

$0.038

Full Release

Summary

Atomo Diagnostics Limited's Appendix 4D and Half Year Report for the period ending 31 December 2025, shows a 6% increase in revenue to AUD 2.18 million and a significant reduction in the net loss by 38% to AUD 1.65 million as compared to the previous year. The company has focused on cost optimization and business development activities, including expanding the OEM customer base and commercializing new tests. Cash and cash equivalents increased to AUD 3.5 million, and significant efforts were made in raising capital and granting employee options to support business growth. The report underscores the commitment to maintaining lean operations and addressing key business risks such as regulatory compliance.

Key Points

Revenues from ordinary activities increased by 6% to AUD 2,180,481.
Loss after tax reduced by 36% to AUD 1,764,894.
No dividends were declared or paid during the period.
Net tangible assets per ordinary security were AUD 0.64.
Capital raise completed with AUD 1,363,611 collected during the half-year.
Cash and cash equivalents at 31 December 2025 were AUD 3.5 million.
Significant focus on cost optimisation and commercialisation of new tests.
Business development included OEM opportunities and expanding product offerings.
No significant changes in state of affairs during the financial half-year.
No subsequent events significantly affecting future operations were noted.

IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.